Mariner LLC Has $3.36 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Mariner LLC boosted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3,749.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 424,291 shares of the company's stock after buying an additional 413,268 shares during the period. Mariner LLC owned 0.14% of Amneal Pharmaceuticals worth $3,360,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Franklin Resources Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 4.9% in the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock valued at $778,000 after acquiring an additional 4,178 shares in the last quarter. Arizona State Retirement System lifted its position in Amneal Pharmaceuticals by 13.6% in the fourth quarter. Arizona State Retirement System now owns 40,401 shares of the company's stock worth $320,000 after purchasing an additional 4,851 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Amneal Pharmaceuticals by 2.5% in the fourth quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock valued at $1,586,000 after buying an additional 4,927 shares during the period. Globeflex Capital L P grew its stake in shares of Amneal Pharmaceuticals by 3.8% in the 4th quarter. Globeflex Capital L P now owns 144,439 shares of the company's stock worth $1,144,000 after purchasing an additional 5,245 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Amneal Pharmaceuticals by 13.6% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock worth $366,000 after purchasing an additional 5,523 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of recent research reports. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays upped their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $10.80.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock traded up $0.06 during mid-day trading on Friday, hitting $7.48. The company's stock had a trading volume of 1,775,605 shares, compared to its average volume of 1,397,425. Amneal Pharmaceuticals, Inc. has a 52-week low of $5.81 and a 52-week high of $9.48. The company has a market cap of $2.32 billion, a PE ratio of -11.00 and a beta of 1.06. The firm's 50 day moving average is $8.06 and its 200 day moving average is $8.20.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million during the quarter, compared to analysts' expectations of $708.21 million. During the same period last year, the company earned $0.14 earnings per share. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the sale, the director now owns 1,888,886 shares of the company's stock, valued at approximately $15,375,532.04. This trade represents a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,160,000 shares of company stock valued at $43,113,200 in the last quarter. Company insiders own 17.45% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.